AlphAIalphai — Financial news for AI agents
ibtimes.co.ukAUG 203 min read$MRNA

Short Sellers Just Lost $5B on the Wrong Pharma Bet: Cancer Vaccine Sends Stock Soaring 177%

Moderna's shares surged 177% after positive Phase 3 trial results for its personalized cancer vaccine, developed with Merck. This caused an estimated $5 billion loss for short sellers, according to S3 Partners. The treatment showed significant improvement in preventing cancer recurrence in melanoma patients. Analysts responded positively, upgrading ratings and describing the results as a landmark win for Moderna.

Original reporting
ibtimes.co.uk
Published Aug 20, 2026, 7:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 7:57 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Short Sellers Just Lost $5B on the Wrong Pharma Bet: Cancer Vaccine Sends Stock Soaring 177% — source image
Source · ibtimes.co.uk
Decision brief

The 30-second read

$MRNABullishHigh
01

Why it matters

The unprecedented 177% jump reflects a shift in market perception and a massive short squeeze.

02

Market read

Breakthrough trial data drives a sharp rally, reshapes outlook for both firms and the broader mRNA oncology space.

03

What to watch

Long‑term commercial viability, manufacturing scale, and competition from other immunotherapies.

Relevance 9/10Novelty 9/10Timing: Wednesday

Background

Moderna's post‑COVID pivot to oncology has faced skepticism; this trial marks a key milestone.

Company-level read

Ticker impact

$MRNABullishHigh confidence
Context

Moderna shares jumped 177% after positive Phase 3 cancer vaccine results with Merck.

Expected impact

Further upside as data is presented at upcoming medical meeting.

Evidence & confidence

Phase 3 data is a material breakthrough for a large‑cap biotech, driving a massive short squeeze and attracting new buying.

$MRKBullishMedium confidence
Context

Merck co‑developed the personalized cancer vaccine that drove Moderna's surge.

Expected impact

Potential modest upside as investors reassess Merck's growth prospects.

Evidence & confidence

Merck benefits from the partnership but its own stock move was less dramatic; impact depends on further data and regulatory path.

Market effects

Sector

Strengthens confidence in mRNA oncology approaches, may lift biotech sector.

Regional

U.S. biotech and pharma markets see heightened interest.

Global

Highlights potential for mRNA tech beyond vaccines, influencing global pharma R&D.

Counterpoint

What could challenge this read

Short sellers may argue data is early and regulatory approval uncertain, keeping downside risk.

Key entities

  • Company
    Moderna Inc.

    mRNA vaccine developer expanding into cancer therapeutics.

  • Company
    Merck & Co.

    Pharmaceutical partner providing Keytruda immunotherapy.

Read at source← All news

Related articles

AUG 20
$DEMed

Premarket movers: Deere jumps following upbeat Q3, Wolfspeed plunges

Deere shares rose 5.1% after reporting stronger-than-expected Q3 results, with EPS of $5.10 and net sales of $11B. CrowdStrike fell 2.8% following its CTO's departure. Advance Auto Parts dropped 15.9% due to lower normalized earnings. Etsy gained 3.9% after a BofA upgrade. Ultragenyx surged 11.1% on FDA approval for a gene therapy. Moderna fell 13% after a prior surge. Wolfspeed plunged 10.5% on wider-than-expected Q4 loss. Webull rose 13.8% on strong Q2 results.

investing.com3 min
AUG 20
$MRNAHighAI 9/10

3 Stocks Soared, 3 Stocks Slumped

Moderna (MRNA) shares surged 176.97% to $174.38 after a successful cancer therapy trial with Merck (MRK). Estee Lauder (EL) rose 16% to $98.01, reporting $3.63B revenue and raising its margin forecast. MicroStrategy (MSTR) gained 12.68% as Bitcoin prices rose. Nebius (NBIS) fell 10% after a $4.5B convertible note offering. Seagate (STX) dropped 8% to $832.56.

baystreet.ca2 min
AUG 20
$MRNAMedAI 8/10

Moderna stock pulls back after massive one-day rally: analysts weigh in

Moderna (MRNA) shares fell over 10% in premarket trading after a 177% rally on positive melanoma vaccine trial data with Merck (MRK). Merck shares also slipped over 1%. Bank of America upgraded Moderna to Neutral, raising its price target to $170, citing the potential for diversification. Merck's Buy rating was reaffirmed with a $166 target. Both companies' stocks were impacted by the trial results.

investing.com2 min
AUG 20
$MRNAHighAI 8/10

After Moderna stock surge of 177% on cancer drug breakthrough, here's what Wall Street thinks happens next

Moderna (MRNA) shares fell 12% in pre-market trading after a 177% gain following a successful Phase 3 trial for its cancer vaccine, intismeran, in partnership with Merck. The vaccine, combined with Merck's Keytruda, showed a significant reduction in melanoma recurrence. Analysts from Jefferies, BofA, and Citigroup commented on the potential implications for Moderna and related companies.

yahoo.com2 min